Published in Perit Dial Int on September 13, 2002
Newer antibiotics for the treatment of peritoneal dialysis-related peritonitis. Clin Kidney J (2016) 0.85
The influence of different peritoneal dialysis fluids on the in vitro activity of ampicillin, daptomycin, and linezolid against Enterococcus faecalis. Eur J Clin Microbiol Infect Dis (2015) 0.75
An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med (2006) 5.02
Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med (2007) 2.86
Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Am J Respir Crit Care Med (2003) 2.56
Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy. Am J Respir Crit Care Med (2004) 2.40
Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. Clin Infect Dis (2009) 2.36
Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis (2005) 2.34
Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis. Am J Respir Crit Care Med (2005) 2.21
Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother (2006) 2.18
Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob Agents Chemother (2011) 1.99
The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. Am J Respir Crit Care Med (2012) 1.94
Potent twice-weekly rifapentine-containing regimens in murine tuberculosis. Am J Respir Crit Care Med (2006) 1.90
Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother (2012) 1.83
Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis. Am J Respir Crit Care Med (2013) 1.65
Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrob Agents Chemother (2012) 1.63
Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana. Clin Infect Dis (2005) 1.61
Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig. J Infect Dis (2009) 1.49
Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. Am J Respir Crit Care Med (2008) 1.47
Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig. J Antimicrob Chemother (2010) 1.40
PA-824 exhibits time-dependent activity in a murine model of tuberculosis. Antimicrob Agents Chemother (2010) 1.38
Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs (2014) 1.34
Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis. Clin Infect Dis (2009) 1.32
Population pharmacokinetic modeling of pyrazinamide in children and adults with tuberculosis. Pharmacotherapy (2002) 1.31
Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin. Antimicrob Agents Chemother (2007) 1.26
Population pharmacokinetics of linezolid in adults with pulmonary tuberculosis. Antimicrob Agents Chemother (2009) 1.24
Paediatric use of second-line anti-tuberculosis agents: a review. Tuberculosis (Edinb) (2011) 1.19
Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis. Antimicrob Agents Chemother (2010) 1.17
The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis. Clin Infect Dis (2005) 1.17
Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors. Bioorg Med Chem Lett (2008) 1.15
Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations. Antimicrob Agents Chemother (2008) 1.14
Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice. Am J Respir Crit Care Med (2011) 1.13
Tuberculosis pharmacotherapy: strategies to optimize patient care. Expert Opin Pharmacother (2009) 1.08
Therapeutic drug monitoring of antimycobacterial drugs in patients with both tuberculosis and advanced human immunodeficiency virus infection. Pharmacotherapy (2009) 1.06
Intestinal permeability and malabsorption of rifampin and isoniazid in active pulmonary tuberculosis. Braz J Infect Dis (2006) 1.05
Factors associated with medication-related problems in ambulatory hemodialysis patients. Am J Kidney Dis (2003) 1.02
Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis. Antimicrob Agents Chemother (2013) 1.00
Metronidazole lacks antibacterial activity in guinea pigs infected with Mycobacterium tuberculosis. Antimicrob Agents Chemother (2008) 0.99
Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigs. Antimicrob Agents Chemother (2012) 0.98
Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery. Pharm Res (2009) 0.94
Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis. Clin Infect Dis (2005) 0.94
Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen. Antimicrob Agents Chemother (2013) 0.94
Serum concentrations of rifampin, isoniazid, and intestinal absorption, permeability in patients with multidrug resistant tuberculosis. Am J Trop Med Hyg (2009) 0.93
Front-loaded linezolid regimens result in increased killing and suppression of the accessory gene regulator system of Staphylococcus aureus. Antimicrob Agents Chemother (2012) 0.93
Linezolid tissue penetration and serum activity against strains of methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility in diabetic patients with foot infections. J Antimicrob Chemother (2007) 0.91
Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment? Eur Respir J (2013) 0.91
Kinetics and determining factors of the virologic response to antiretrovirals during pregnancy. Infect Dis Obstet Gynecol (2010) 0.89
Comparison of linezolid activities under aerobic and anaerobic conditions against methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother (2003) 0.89
CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics? Pharmacotherapy (2014) 0.88
Pharmacodynamics of early, high-dose linezolid against vancomycin-resistant enterococci with elevated MICs and pre-existing genetic mutations. J Antimicrob Chemother (2012) 0.87
Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation. Antimicrob Agents Chemother (2009) 0.86
The potent bactericidal activity of streptomycin in the guinea pig model of tuberculosis ceases due to the presence of persisters. J Antimicrob Chemother (2010) 0.86
Editorial commentary: pharmacokinetic variability and tuberculosis treatment outcomes, including acquired drug resistance. Clin Infect Dis (2012) 0.86
Prediction and in vitro evaluation of selected protease inhibitor antiviral drugs as inhibitors of carboxylesterase 1: a potential source of drug-drug interactions. Pharm Res (2011) 0.83
Preliminary pharmacokinetic study of repeated doses of rifampin and rifapentine in guinea pigs. Antimicrob Agents Chemother (2013) 0.82
Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis. Ann Pharmacother (2005) 0.82
The clinical pharmacokinetics of pyrazinamide in HIV-infected persons with tuberculosis. Clin Infect Dis (2004) 0.80
Posaconazole pharmacokinetics in a 2-year-old boy with rhino-cerebral-orbital zygomycosis. Pharmacotherapy (2013) 0.80
Factors associated with variability in rifampin plasma pharmacokinetics and the relationship between rifampin concentrations and induction of efavirenz clearance. Pharmacotherapy (2014) 0.80
Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers. J Antimicrob Chemother (2013) 0.80
Antituberculosis therapy for 2012 and beyond. Expert Opin Pharmacother (2012) 0.80
Mycobacterium avium in pygmy rabbits (Brachylagus idahoensis): 28 cases. J Zoo Wildl Med (2006) 0.79
Concomitant use of voriconazole and rifabutin in a patient with multiple infections. Pharmacotherapy (2008) 0.78
Poor absorption of high-dose posaconazole in pediatric bone marrow transplant patients. Ann Pharmacother (2012) 0.78
Gentamicin pharmacokinetics during slow daily home hemodialysis. Kidney Int (2003) 0.78
Peritoneal dialysis fluid concentrations of linezolid in the treatment of vancomycin-resistant Enterococcus faecium peritonitis. Pharmacotherapy (2003) 0.78
Activity of the fluoroquinolone DC-159a in the initial and continuation phases of treatment of murine tuberculosis. Antimicrob Agents Chemother (2011) 0.78
Treatment of a tuberculous empyema with simultaneous oral and intrapleural antituberculosis drugs. Can Respir J (2008) 0.78
Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection. Pharmacotherapy (2007) 0.78
Clearance of linezolid via continuous venovenous hemodiafiltration. Am J Kidney Dis (2006) 0.77
Intestinal barrier function and serum concentrations of rifampin, isoniazid and pyrazinamide in patients with pulmonary tuberculosis. Braz J Infect Dis (2009) 0.77
Stability of antituberculosis drugs mixed in food. Clin Infect Dis (2007) 0.77
Linezolid clearance during continuous venovenous hemodiafiltration: a case report. Pharmacotherapy (2003) 0.77
Pharmacokinetic mismatch of tuberculosis drugs. Antimicrob Agents Chemother (2012) 0.76
Mycobacterium tuberculosis Infection among Asian Elephants in Captivity. Emerg Infect Dis (2017) 0.75
Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections. Pharmacogenet Genomics (2017) 0.75
Rifamycin treatment of tuberculosis in a patient receiving atenolol: less interaction with rifabutin than with rifampin. Clin Infect Dis (2003) 0.75
Long-term and per rectum disposition of Clarithromycin in the desert tortoise (Gopherus agassizii). J Am Assoc Lab Anim Sci (2008) 0.75
Pharmacokinetics and Dosing of Levofloxacin in Children Treated for Active or Latent Multidrug-resistant Tuberculosis, Federated States of Micronesia and Republic of the Marshall Islands. Pediatr Infect Dis J (2016) 0.75
Reply to "Contradictory results with high-dosage rifamycin in mice and humans". Antimicrob Agents Chemother (2013) 0.75
Evaluation of the Adequacy of the 2010 Revised World Health Organization Recommended Dosages of the First-line Antituberculosis Drugs for Children. Pediatr Infect Dis J (2017) 0.75
ISONIAZID AND RIFAMPIN PHARMACOKINETICS IN TWO ASIAN ELEPHANTS (ELEPHAS MAXIMUS) INFECTED WITH MYCOBACTERIUM TUBERCULOSIS. J Zoo Wildl Med (2016) 0.75
Population pharmacokinetics of antituberculous drugs and treatment of Mycobacterium bovis infection in bongo antelope (Tragelaphus eurycerus isaaci). J Zoo Wildl Med (2002) 0.75
Bile and gallbladder tissue concentrations of moxifloxacin in patients with acute cholecystitis. Ann Pharmacother (2010) 0.75
Pharmacokinetics of antituberculosis medications delivered via percutaneous gastrojejunostomy tube. Chest (2002) 0.75